种族和族裔少数群体退伍军人中的阿片类药物及高风险处方
该研究基于2018年退伍军人健康管理局使用者和参保者的电子健康记录进行横断面分析,比较不同种族和族裔退伍军人的阿片类药物处方及高风险处方情况。总体14.8%接受了阿片类药物处方;与非西班牙裔白人退伍军人相比,除非西班牙裔多种族和非西班牙裔美洲印第安人/阿拉斯加原住民外,其他种族/族裔组接受阿片类药物处方的调整比值比更低。非西班牙裔白人和非西班牙裔美洲印第安人/阿拉斯加原住民退伍军人接受阿片类药物处方的可能性最大,且在高风险处方方面也更为常见。
要点
- 总体14.8%的退伍军人接受了阿片类药物处方。
- 非西班牙裔白人和非西班牙裔美洲印第安人/阿拉斯加原住民退伍军人接受阿片类药物处方的可能性最大。
- 当处方阿片类药物时,白人和美洲印第安人/阿拉斯加原住民退伍军人中的高风险处方比其他种族/族裔组更常见。
核心结论
- 非西班牙裔白人和非西班牙裔美洲印第安人/阿拉斯加原住民退伍军人接受阿片类药物处方的可能性最大。
- 当处方阿片类药物时,白人和美洲印第安人/阿拉斯加原住民退伍军人中的高风险处方比其他所有种族/族裔组更常见。
- 作为美国最大的整合医疗系统,退伍军人健康管理局可以制定和测试干预措施,以实现疼痛患者的健康公平。
研究设计与样本
- 对2018年退伍军人健康管理局使用者和参保者的电子健康记录数据进行横断面分析,比较退伍军人特征和医疗服务使用情况。
主要发现
- 总体14.8%接受了阿片类药物处方。
- 与非西班牙裔白人退伍军人相比,所有种族/族裔组接受阿片类药物处方的调整比值比更低,但非西班牙裔多种族(AOR=1.03;95% CI=0.999, 1.05)和非西班牙裔美洲印第安人/阿拉斯加原住民(AOR=1.06;95% CI=1.03, 1.09)除外。
- 与非西班牙裔白人组相比,所有种族/族裔组出现任何一天阿片类药物重叠处方的比值比更低,但非西班牙裔美洲印第安人/阿拉斯加原住民组(AOR=1.01;95% CI=0.96, 1.07)除外。
- 与非西班牙裔白人组相比,所有种族/族裔组出现任何一天日剂量>120吗啡毫克当量的比值比更低,但非西班牙裔多种族(AOR=0.96;95% CI=0.87, 1.07)和非西班牙裔美洲印第安人/阿拉斯加原住民(AOR=1.06;95% CI=0.96, 1.17)组除外。
- 非西班牙裔亚洲退伍军人出现任何一天阿片类药物重叠处方(AOR=0.54;95% CI=0.50, 0.57)和日剂量>120吗啡毫克当量(AOR=0.43;95% CI=0.36, 0.52)的比值比最低;对于任何一天阿片类药物-苯二氮䓬类药物重叠处方,所有种族/族裔组的比值比均低于非西班牙裔白人,其中非西班牙裔黑人或非洲裔美国人(AOR=0.71;95% CI=0.70, 0.72)和非西班牙裔亚洲人(AOR=0.73;95% CI=0.68, 0.77)退伍军人的比值比最低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The purpose of this study is to compare opioid prescribing and high-risk prescribing by race and ethnicity in a national cohort of U.S. veterans. METHODS: A cross-sectional analysis of veteran characteristics and healthcare use was performed on electronic health record data for 2018 Veterans Health Administration users and enrollees in 2022. RESULTS: Overall, 14.8% received an opioid prescription. The adjusted odds of being prescribed an opioid were lower for all race/ethnicity groups than for non-Hispanic White veterans, except for non-Hispanic multiracial (AOR=1.03; 95% CI=0.999, 1.05) and non-Hispanic American Indian/Alaska Native (AOR=1.06; 95% CI=1.03, 1.09) veterans. The odds of any day of overlapping opioid prescriptions (i.e., opioid overlap) were lower for all race/ethnicity groups than for the non-Hispanic White group, except for the non-Hispanic American Indian/Alaska Native group (AOR=1.01; 95% CI=0.96, 1.07). Similarly, all race/ethnicity groups had lower odds of any day of daily dose >120 morphine milligram equivalents than the non-Hispanic White group, except for the non-Hispanic multiracial (AOR=0.96; 95% CI=0.87, 1.07) and non-Hispanic American Indian/Alaska Native (AOR=1.06; 95% CI=0.96, 1.17) groups. Non-Hispanic Asian veterans had the lowest odds for any day of opioid overlap (AOR=0.54; 95% CI=0.50, 0.57) and daily dose >120 morphine milligram equivalents (AOR=0.43; 95% CI=0.36, 0.52). For any day of opioid-benzodiazepine overlap, all races/ethnicities had lower odds than non-Hispanic White. Non-Hispanic Black/African American (AOR=0.71; 95% CI=0.70, 0.72) and non-Hispanic Asian (AOR=0.73; 95% CI=0.68, 0.77) veterans had the lowest odds of any day of opioid-benzodiazepine overlap. CONCLUSIONS: Non-Hispanic White and non-Hispanic American Indian/Alaska Native veterans had the greatest likelihood to receive an opioid prescription. When an opioid was prescribed, high-risk prescribing was more common in White and American Indian/Alaska Native veterans than in all other racial/ethnic groups. As the nation's largest integrated healthcare system, the Veterans Health Administration can develop and test interventions to achieve health equity for patients experiencing pain.
引用
- Suda KJ, Boyer TL, Blosnich JR, et al. Opioid and High-Risk Prescribing Among Racial and Ethnic Minority Veterans. Am J Prev Med. 2023. PMID: 37302514. doi:10.1016/j.amepre.2023.06.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。